selgantolimod
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 6, 2018 (NCT03491553)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Toll-like receptor 8AGONIST
Toll-like receptor 8 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCC[C@](C)(CO)Nc1nc(N)nc2cc(F)cnc12- Mol. weight
- 293.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594258 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05551273 | Phase 2 | Dec 14, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04891770 | Phase 2 | Aug 14, 2021 | Gilead Sciences, Vir Biotechnology, Inc. |
| NCT03491553 | Phase 2 | Apr 6, 2018 | Gilead Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 2 | 2 | 1 | 2018 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2022 |
| Vir Biotechnology, Inc. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1